Back to Results
First PageMeta Content
Nitric oxide / Vasodilation / Portopulmonary hypertension / Iloprost / Chemistry / Hypertension / Pulmonary hypertension


FDA GRANTS ORPHAN DRUG DESIGNATION TO IKARIA® FOR USE OF INHALED NITRIC OXIDE IN PULMONARY ARTERIAL HYPERTENSION -- Investigational New Drug Application Submitted -- Hampton, NJ – January 23, 2012 – Ikaria, Inc., a
Add to Reading List

Document Date: 2012-01-30 17:01:52

Open Document

File Size: 86,16 KB

Share Result on Facebook

City

Madison / Hampton / /

Company

Ikaria Inc. / /

Country

Puerto Rico / Japan / United States / Canada / Australia / Mexico / /

Event

FDA Phase / /

Facility

Port Allen / /

IndustryTerm

drug-device combination product / drug product / combination product / treatment of hypoxic respiratory failure / drugdevice combination product / manufacturing facilities / gas mixtures / treatment for Hepatorenal Syndrome / /

MedicalCondition

bronchopulmonary dysplasia / rare diseases / hypertension / pulmonary arterial hypertension / chronic obstructive pulmonary disease / IN PULMONARY ARTERIAL HYPERTENSION / airway inflammation / pulmonary hypertension / subsequent congestive heart failure / pulmonary vasculature / hypoxic respiratory failure / Methemoglobinemia / disorders / acute myocardial infarction / /

MedicalTreatment

innovative therapies / extracorporeal membrane oxygenation / /

Organization

U.S. Food and Drug Administration / FDA / /

Person

Daniel Tassé / /

Position

Chairman and CEO / /

Product

INOMAX / PAH / INOpulse / INOpulse® DS / DS / /

ProvinceOrState

New Jersey / Wisconsin / Indiana / /

Technology

drug-delivery system / /

URL

www.ikaria.com / www.inomax.com / /

SocialTag